Telix Pharmaceuticals (TLX) H.C. Wainwright 28th Annual Global Investment Conference summary

Business overview and infrastructure

• Vertically integrated theranostic radiopharmaceutical company with both imaging and therapeutic products for each target.

• Imaging business commercialized, generating about $1 billion in sales, mainly from prostate cancer imaging, with recent brain cancer approval.

• Major focus areas are urology and neuro-oncology, with additional rare disease work.

• Built global supply chain and manufacturing infrastructure, delivering about 3 million patient doses last year.

• Owns radiopharmacy distribution network in the U.S. and manufacturing facilities in Europe, Japan, and Australia.

Financial guidance and outlook

• Guidance for 2026 revised toward the upper end following a strong first half.

• Current year guidance maintained, with positive business trajectory.

Precision medicine and imaging pipeline

• FDA approved Pixclara, the first PET imaging agent for glioma, addressing a significant unmet need.

• Market opportunity for Pixclara estimated at 20,000–25,000 scans, with potential for multiple scans per patient.

• Initial Pixclara business expected to be a couple hundred million dollars, with further TAM expansion into metastatic brain tumors.

• Completed enrollment in phase III BiPASS trial for prostate cancer detection, aiming to move PSMA PET imaging before biopsy.

• BiPASS trial design integrates PSMA PET into standard care, potentially reducing unnecessary biopsies and improving surgical outcomes.

• BiPASS trial readout expected around the end of next year or early in the new year.